illustration of a lion's head overlaid on a man's face

Cancer detection that's as determined as you are.

Facing cancer takes courage. clonoSEQ helps doctors detect, quantify, and monitor small amounts of cancer known as measurable (or minimal) residual disease (MRD) to inform treatment throughout a patient’s care. So you can approach cancer measurement with the same strength and bravery as cancer treatment.1

Select the disease state for you or someone you love

I am a healthcare professional
Myeloma
DLBCL
CLL
Adult ALL
Pediatric ALL
MCL
A different type of blood cancer
I am a healthcare professional

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

Reference:

  1. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.